Skip to main content

Table 6 Classification accuracies for the independent test set.

From: Non-negative matrix factorisation methods for the spectral decomposition of MRS data from human brain tumours

LTE, FE method:PCA

     

A2, NO(2PC)

A2, ME, NO(3PC)

A2, GL, NO(3PC)

A2, MM, NO(3PC)

A2, AG, NO(4PC)

A2, AG, MM(4PC)

Total:92.3%(12/13)

Total:82.6%(19/23)

Total:65.1%(28/43)

Total:81.3%(13/16)

Total:64.2%(34/53)

Total:67.9%(36/53)

A2:100%(10/10)

A2:100%(10/10)

A2:90%(9/10)

A2:80.0%(8/10)

A2:90%(9/10)

A2:80.0%(8/10)

NO:66.7%(2/3)

ME:70.0%(7/10)

GL:53.3%(16/30)

MM:66.7%(2/3)

AG:57.5%(23/40)

AG:62.5%(25/40)

 

NO:66.7%(2/3)

NO:100%(3/3)

NO:100%(3/3)

NO:66.7%(2/3)

MM:100%(3/3)

BER:0.17

BER:0.21

BER:0.19

BER:0.18

BER:0.29

BER:0.19

LTE, FE method:Convex-NMF

     

A2, NO(2SS)

A2, ME, NO(3SS)

A2, GL, NO(3SS)

A2, MM, NO(3SS)

A2, AG, NO(4SS)

A2, AG, MM(4SS)

Total:92.3%(12/13)

Total:82.6%(19/23)

Total:67.4%(29/43)

Total:68.8(11/16)

Total:71.7%(38/53)

Total:64.2%(34/53)

A2:90.0%(9/10)

A2:90.0%(9/10)

A2:70.0%(7/10)

A2:50.0%(5/10)

A2:70.0%(7/10)

A2:60%(6/10)

NO:100%(3/3)

ME:70.0%(7/10)

GL:63.3%(19/30)

MM:100%(3/3)

AG:70.0%(28/40)

AG:62.5%(25/40)

 

NO:100%(3/3)

NO:100%(3/3)

NO:100%(3/3)

NO:100%(3/3)

MM:100%(3/3)

BER:0.05

BER:0.13

BER:0.22

BER:0.17

BER:0.20

BER:0.26

STE, FE method:PCA

     

A2, NO(2PC)

A2, ME, NO(3PC)

A2, GL, NO(3PC)

A2, MM, NO(3PC)

A2, AG, NO(4PC)

A2, AG, MM(4PC)

Total:92.3%(12/13)

Total:73.9%(17/23)

Total:76.7%(33/43)

Total:75.0(12/16)

Total:83.0%(44/53)

Total:73.6%(39/53)

A2:90.0%(9/10)

A2:80.0%(8/10)

A2:60.0%(6/10)

A2:60.0%(6/10)

A2:80.0%(8/10)

A2:70.0%(7/10)

NO:100%(3/3)

ME:70.0%(7/10)

GL:80.0%(24/30)

MM:100%(3/3)

AG:87.5%(35/40)

AG:72.5%(29/40)

 

NO:66.7%(2/3)

NO:100%(3/3)

NO:100%(3/3)

NO:33.3%(1/3)

MM:100%(3/3)

BER:0.05

BER:0.28

BER:0.20

BER:0.13

BER:0.33

BER:0.19

STE, FE method:Convex-NMF

     

A2, NO(2SS)

A2, ME, NO(3SS)

A2, GL, NO(3SS)

A2, MM,NO(3SS)

A2, AG, NO(4SS)

A2, AG, MM(4SS)

Total:92.3%(12/13)

Total:91.3%(21/23)

Total:90.7%(39/43)

Total:87.5(14/16)

Total:90.6%(48/53)

Total:83.0%(44/53)

A2:90.0%(9/10)

A2:90.0%(9/10)

A2:90.0%(9/10)

A2:80.0%(8/10)

A2:90.0%(9/10)

A2:90.0%(9/10)

NO:100%(3/3)

ME:90.0%(9/10)

GL:90.0%(27/30)

MM:100%(3/3)

AG:90.0%(36/40)

AG:80.0%(32/40)

 

NO:100%(3/3)

NO:100%(3/3)

NO:100%(3/3)

NO:100%(3/3)

MM:100%(3/3)

BER:0.05

BER:0.07

BER:0.07

BER:0.07

BER:0.07

BER:0.10

  1. Classification accuracies (total and by tumour type) and balanced error rates (BER) for the independent test set, using all the classification settings from Tables 4 and 5, for data at LTE and STE